Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania - PubMed (original) (raw)
Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania
Auksė Domeikienė et al. Medicina (Kaunas). 2014.
Free article
Abstract
Objective: The main objective of this study was to estimate the annual direct healthcare cost of type 2 diabetes mellitus healthcare and its complications in Lithuanian population.
Material and methods: The study uses a prevalence-based top-down approach. The random sample of study participants was formed using the database of the National Health Insurance Fund under the Lithuanian Ministry of Health. 762 patients with diabetes mellitus type 2 data were analyzed in this research. The data on healthcare costs was recorded between January 1, 2011 and December 31, 2011.
Results: Ambulatory care cost mean per patients with diabetes mellitus type 2 in 2011 was EUR 156.14 (95% CI, 147.05-165.24). 34.4% patients had at least one hospitalization during the 2011 year. Mean annual cost per patients of hospitalization was EUR 1160.16 (95% CI, 1019.60-1300.73). Covered drugs and diabetes supplies annual direct cost mean per patients was EUR 448.34 (95% CI, 411.14-485.54). The more expensive treatment was with oral and non-insulin injectable hypoglycemic medications (P<0.001). 65.1% participants were diagnosed one or more diabetes-related chronic complications. Average annual cost per person, increased gradually with the numbers of complications from EUR 671.94 (95% CI, 575.03-768.86) in patients without complications to EUR 1588.98 (95% CI, 1052.09-2125.86) in patients with 3 and more complications (P<0.001).
Conclusions: The largest part of direct costs in diabetes mellitus healthcare composes hospital inpatient care and covered drugs expenditures. In our study we observed that the presence of microvascular, macrovascular chronic complication increased the direct cost per patient, compared with patients without complications.
Keywords: Cost analysis; Diabetes mellitus type 2; Diabetes-related chronic complications; Direct cost.
Copyright © 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Similar articles
- Assessment of hospital length of stay and direct costs of type 2 diabetes in Hubei Province, China.
Chen D, Liu S, Tan X, Zhao Q. Chen D, et al. BMC Health Serv Res. 2017 Mar 14;17(1):199. doi: 10.1186/s12913-017-2140-4. BMC Health Serv Res. 2017. PMID: 28288623 Free PMC article. - The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory.
Pagano E, De Rosa M, Rossi E, Cinconze E, Marchesini G, Miccoli R, Vaccaro O, Bonora E, Bruno G. Pagano E, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):944-50. doi: 10.1016/j.numecd.2016.05.002. Epub 2016 May 24. Nutr Metab Cardiovasc Dis. 2016. PMID: 27289165 - The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system.
Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leão MP, Ramos AJ, Forti AC, Gomes MB, Foss MC, Monteiro RA, Sartorelli D, Franco LJ. Bahia LR, et al. Value Health. 2011 Jul-Aug;14(5 Suppl 1):S137-40. doi: 10.1016/j.jval.2011.05.009. Value Health. 2011. PMID: 21839888 - The impact of diabetes mellitus on healthcare costs in Italy.
Giorda CB, Manicardi V, Diago Cabezudo J. Giorda CB, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-19. doi: 10.1586/erp.11.78. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 22098288 Review. - Cost analysis of type 2 diabetes mellitus treatment in economically developed countries.
Ramzan S, Timmins P, Hasan SS, Babar ZU. Ramzan S, et al. Expert Rev Pharmacoecon Outcomes Res. 2019 Feb;19(1):5-14. doi: 10.1080/14737167.2018.1513790. Epub 2018 Sep 4. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 30146917 Review.
Cited by
- Cost of maternal complications and its associated factors among mothers attending Hawassa public hospitals, Southern Ethiopia.
Loko D, Ayele A, Dessie Y, Hawulte B, Ayele G, Tolossa T. Loko D, et al. J Public Health Res. 2023 Nov 29;12(4):22799036231215993. doi: 10.1177/22799036231215993. eCollection 2023 Oct. J Public Health Res. 2023. PMID: 38034846 Free PMC article. - The effects of purslane consumption on glycemic control and oxidative stress: A systematic review and dose-response meta-analysis.
Jafari N, Shoaibinobarian N, Dehghani A, Rad A, Mirmohammadali SN, Alaeian MJ, Hamedi Y, Zamani M, Goudarzi MA, Asbaghi O. Jafari N, et al. Food Sci Nutr. 2023 Mar 15;11(6):2530-2546. doi: 10.1002/fsn3.3311. eCollection 2023 Jun. Food Sci Nutr. 2023. PMID: 37324837 Free PMC article. Review. - Economic burden of type 2 diabetes in Iran: A cost-of-illness study.
Jalilian H, Heydari S, Imani A, Salimi M, Mir N, Najafipour F. Jalilian H, et al. Health Sci Rep. 2023 Feb 20;6(2):e1120. doi: 10.1002/hsr2.1120. eCollection 2023 Feb. Health Sci Rep. 2023. PMID: 36824619 Free PMC article. - Medications and medical costs for diabetes patients with or without chronic respiratory disease in Beijing, China: A retrospective study.
Qiao J, Tan Z, Xu X, Zhou Y, Wang W, Luo J, Fan J, Pan Q, Guo L. Qiao J, et al. Front Endocrinol (Lausanne). 2022 Aug 26;13:980982. doi: 10.3389/fendo.2022.980982. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36093107 Free PMC article. - Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait.
Alowayesh MS, Aljunid SM, Al-Adsani A, Alessa T, Alattar A, Alroudhan D. Alowayesh MS, et al. PLoS One. 2022 Jun 2;17(6):e0268495. doi: 10.1371/journal.pone.0268495. eCollection 2022. PLoS One. 2022. PMID: 35653361 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical